Last reviewed · How we verify
Febuxostat-Reference product
At a glance
| Generic name | Febuxostat-Reference product |
|---|---|
| Sponsor | Bio-innova Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets (PHASE1)
- Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Febuxostat-Reference product CI brief — competitive landscape report
- Febuxostat-Reference product updates RSS · CI watch RSS
- Bio-innova Co., Ltd portfolio CI